Integrating liquid biopsies into the management of cancer
During cancer progression and treatment, multiple subclonal populations of tumour cells
compete with one another, with selective pressures leading to the emergence of …
compete with one another, with selective pressures leading to the emergence of …
[HTML][HTML] Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC
The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with
considerable potential to improve clinical outcomes across multiple cancer types, including …
considerable potential to improve clinical outcomes across multiple cancer types, including …
Heterogeneity in lung cancer
VML de Sousa, L Carvalho - Pathobiology, 2018 - karger.com
Lung cancer diagnosis is a challenge since it is also one of the most frequently diagnosed
cancers. Diagnostic challenges are deeply related to the development of personalized …
cancers. Diagnostic challenges are deeply related to the development of personalized …
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line …
Purpose: Blood-based circulating-free (cf) tumor DNA may be an alternative to tissue-based
EGFR mutation testing in NSCLC. This exploratory analysis compares matched tumor and …
EGFR mutation testing in NSCLC. This exploratory analysis compares matched tumor and …
[HTML][HTML] Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma
AK Krug, D Enderle, C Karlovich, T Priewasser… - Annals of …, 2018 - Elsevier
Background A major limitation of circulating tumor DNA (ctDNA) for somatic mutation
detection has been the low level of ctDNA found in a subset of cancer patients. We …
detection has been the low level of ctDNA found in a subset of cancer patients. We …
[HTML][HTML] The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?
D Kwapisz - Annals of translational medicine, 2017 - ncbi.nlm.nih.gov
Specific mutations in epidermal growth factor receptor (EGFR) gene are predictive for
response to the EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer patients …
response to the EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer patients …
[HTML][HTML] EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of …
Objectives To assess the ability of different technology platforms to detect epidermal growth
factor receptor (EGFR) mutations, including T790M, from circulating tumor DNA (ctDNA) in …
factor receptor (EGFR) mutations, including T790M, from circulating tumor DNA (ctDNA) in …
Precision oncology: who, how, what, when, and when not?
L Schwartzberg, ES Kim, D Liu… - American Society of …, 2017 - europepmc.org
Precision oncology, defined as molecular profiling of tumors to identify targetable alterations,
is rapidly developing and has entered the mainstream of clinical practice. Genomic testing …
is rapidly developing and has entered the mainstream of clinical practice. Genomic testing …
Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial
N Karachaliou, C Mayo-De Las Casas, C Queralt… - JAMA …, 2015 - jamanetwork.com
Importance The EURTAC trial demonstrated the greater efficacy of erlotinib compared with
chemotherapy for the first-line treatment of European patients with advanced non–small-cell …
chemotherapy for the first-line treatment of European patients with advanced non–small-cell …
Clinical validation of a next-generation sequencing-based multi-cancer early detection “liquid biopsy” blood test in over 1,000 dogs using an independent testing set …
A Flory, KM Kruglyak, JA Tynan, LM McLennan… - PLoS …, 2022 - journals.plos.org
Cancer is the leading cause of death in dogs, yet there are no established screening
paradigms for early detection. Liquid biopsy methods that interrogate cancer-derived …
paradigms for early detection. Liquid biopsy methods that interrogate cancer-derived …